

## [226] INNOVATIVE DIAGNOSTIC PLATFORM FOR EARLY CANCER DETECTION

Yael Glickman<sup>1</sup>, Lerner Guy<sup>1</sup>, <sup>1</sup> Micromedic Technologies Ltd.

- **Investment Rationale**

Micromedic focuses on development and commercialization of innovative diagnostic solutions for early cancer detection with particular focus on bladder cancer, the fourth most common cancer among men in the U.S. The Company is expanding its distribution network in Europe, and has initiated commercial activities with major CLIA laboratories in North America. The Company's leading team combines years of managerial experience in biomed industry.

- **Business Strategy**

Micromedic is developing a valuable pipeline of diagnostic solutions based on its core CellDetect® technological platform. The Company generates near term revenues from commercialization of its bladder and cervical cancer tests. For long-term revenues, the Company is engaged in the development of its prostate cancer test to answer the unmet diagnostic need of millions of patients worldwide.

- **Core Technology**

CellDetect® is a breakthrough noninvasive diagnostic platform which, as opposed to standard methods, uses both color and morphology in order to differentiate between normal and cancer cells. This color feature dramatically enhances the diagnostic accuracy across all cancer stages, affording high sensitivity for early stage tumors which may be missed by usual noninvasive tests.

- **Product Profile/Pipeline**

CellDetect® technological platform targets multiple cancer applications. While focusing on commercialization of its bladder cancer test, Micromedic continues to promote its cervical cancer assay to emerging markets and was selected by the World Bank to conduct pilots with laboratory chains in India. In addition, the Company expands its CellDetect® platform to additional cancer applications including prostate cancer.

- **What's Next?**

Micromedic is pursuing the development of its CellDetect® platform to address unmet diagnostic needs of additional cancer populations. Particularly, the Company is conducting an extended clinical study for the detection of prostate cancer in urine.

The company is seeking both strategic and financial investments to support the development and commercialization of its diagnostic solutions.